Education
About Us
Working with TipRanks
Follow Us
Innovative Pharmaceutical Biotech Limited (HK:0399)
:0399
0399 Stock Chart & Stats
HK$0.09
>-HK$0.01(-3.77%)
At close: 4:00 PM EST
HK$0.09
>-HK$0.01(-3.77%)
Day’s Range― - ―
52-Week RangeHK$0.05 - HK$0.73
Previous CloseN/A
Volume1.53M
Average Volume (3M)17.09M
Market Cap
HK$413.56M
Enterprise ValueHK$1.49B
Total Cash (Recent Filing)HK$18.07M
Total Debt (Recent Filing)HK$1.09B
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding2,142,787,600
10 Day Avg. Volume17,323,689
30 Day Avg. Volume17,085,593
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.44
Price to Sales (P/S)143.85
P/FCF Ratio-28.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intermittent ProfitabilityReported profits in 2022 and 2024 demonstrate the business can generate positive operating results under certain conditions. This indicates underlying product demand and margin levers exist, implying management can achieve profitability if revenue stabilizes and cost controls persist.
Improving Cash Generation TrendThe reduction in cash burn and positive free cash flow growth in the latest year suggests operations and working capital are moving toward improved cash generation. A sustained improvement reduces dependency on external financing and supports longer-term solvency if maintained.
Defensive Industry ExposureOperating in household and personal products provides structurally stable end-market demand and recurring consumption patterns. This sector resilience creates a demand floor that can support revenue recovery and margin normalization when operational issues are addressed.
Bears Say
Negative Equity And Heavy LeverageNegative equity paired with very large debt indicates structural solvency stress. This constrains financing options, increases refinancing and covenant risk, and limits capacity for investment or weathering further shocks, raising the probability of distress absent balance sheet repair.
Severe Revenue ContractionA steep ~53% revenue drop in 2025, following multi-year contraction, undermines scale economics and makes margin recovery harder. Persistent top-line decline weakens pricing power and distribution relationships and raises uncertainty about the firm's ability to return to stable growth.
Persistent Negative Operating Cash FlowConsistent negative operating and free cash flow means the core business does not self-fund, forcing reliance on external financing or asset moves. Over months this increases liquidity and refinancing risk and can lead to higher costs, dilution, or restructuring if trends persist.
Innovative Pharmaceutical Biotech News
0399 FAQ
What was Innovative Pharmaceutical Biotech Limited’s price range in the past 12 months?
Innovative Pharmaceutical Biotech Limited lowest stock price was HK$0.05 and its highest was HK$0.73 in the past 12 months.
What is Innovative Pharmaceutical Biotech Limited’s market cap?
Innovative Pharmaceutical Biotech Limited’s market cap is HK$413.56M.
When is Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date?
Innovative Pharmaceutical Biotech Limited’s upcoming earnings report date is Jun 25, 2026 which is in 100 days.
How were Innovative Pharmaceutical Biotech Limited’s earnings last quarter?
Innovative Pharmaceutical Biotech Limited released its earnings results on Nov 28, 2025. The company reported -HK$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.06.
Is Innovative Pharmaceutical Biotech Limited overvalued?
According to Wall Street analysts Innovative Pharmaceutical Biotech Limited’s price is currently Overvalued.
Does Innovative Pharmaceutical Biotech Limited pay dividends?
Innovative Pharmaceutical Biotech Limited does not currently pay dividends.
What is Innovative Pharmaceutical Biotech Limited’s EPS estimate?
Innovative Pharmaceutical Biotech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Innovative Pharmaceutical Biotech Limited have?
Innovative Pharmaceutical Biotech Limited has 2,142,787,600 shares outstanding.
What happened to Innovative Pharmaceutical Biotech Limited’s price movement after its last earnings report?
Innovative Pharmaceutical Biotech Limited reported an EPS of -HK$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.976%.
Which hedge fund is a major shareholder of Innovative Pharmaceutical Biotech Limited?
Currently, no hedge funds are holding shares in HK:0399
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovative Pharmaceutical Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.92%
12-Months-Change
Fundamentals
Return on Equity
76.98%
Trailing 12-Months
Asset Growth
-19.45%
Trailing 12-Months
Company Description
Innovative Pharmaceutical Biotech Limited
Innovative Pharmaceutical Biotech Limited, an investment holding company, engages in the trading of beauty equipment and products in the People's Republic of China and Hong Kong. The company operates in two segments, Trading of Beauty Products, and Research and Development. It is also involved in the securities investment; research, development, and commercialization of oral insulin products; distribution of bio-industrial products; and provision of genetic testing services. The company was formerly known as United Gene High-Tech Group Limited and changed its name to Innovative Pharmaceutical Biotech Limited in September 2015. Innovative Pharmaceutical Biotech Limited is headquartered in Sheung Wan, Hong Kong.
Technical Analysis
Natural Beauty Bio-Technology
―
EC Healthcare
―
Giant Biogene Holding Co. Ltd.
―
Nanjing Sinolife United Co., Ltd. Class H
―
Blue Moon Group Holdings Ltd.
―